Results 111 to 120 of about 39,781 (168)

A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). [PDF]

Clin Infect Dis
Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM.   +15 more
europepmc   +1 more source

Antiretroviral regimen switch and short-term viral suppression in persistent low-level viremia: A multicenter retrospective real-world cohort study in China. [PDF]

PLoS One
Liu H, Ren Y, Jia L, Wang L, Wang R, Yang T, Zhou Y, Zhao H, Dai L.   +8 more
europepmc   +1 more source

Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023. [PDF]

China CDC Wkly
Jia H, Zhao Y, Guan Y, Liu J, Geng Y, Gan X, Liu Y.   +6 more
europepmc   +1 more source

Beyond HIV: investigating key drivers of metabolic syndrome in midlife women with HIV in the INSTI era. [PDF]

AIDS Res Ther
Poliseno M, Brindicci G, Capruzzi D, Cianciaruso A, Colavito N, Giliberti V, Lobalsamo V, Metrangolo G, Milano E, Perrucci L, Santoro CR, Vigna A, Di Gennaro F, Saracino A.   +13 more
europepmc   +1 more source

Low Prevalence of Integrase Inhibitor Resistance Following Treatment Failure: A Real-World Analysis from Hunan Province, China. [PDF]

Infect Drug Resist
Zou X, Zhang J, Liu W, Wei X, Zhou J, Chen H.   +5 more
europepmc   +1 more source

HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy. [PDF]

J Antimicrob Chemother
Abdullahi A, Osawe S, Wisso H, Edun M, Adebisi G, Arachie J, Ude C, Onyemata J, Alhaji SY, Bara Jibrin Y, Abimiku A, Kemp SA, Gupta RK.   +12 more
europepmc   +1 more source

A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab. [PDF]

Open Forum Infect Dis
Stefic K, Tumiotto C, de Monte A, Wirden M, Rodallec A, Fofana D, Chaix ML, Bellecave P, Garnier E, Sourice J, Vellas C, Raymond S, Lambert-Niclot S, Alidjinou EK, Coulon P, Avettand-Fenoel V, Mchantaf G, Handala L, Alessandri-Gradt E, Moisan A, Lê M, Delaugerre C, Marcelin AG, Peytavin G, Calvez V, Descamps D, Charpentier C, Entry Inhibitors Observatory Study Group, Entry Inhibitors Observatory Study Group .   +28 more
europepmc   +1 more source

Multiclass HIV drug resistance: Case series of treatment-experienced PLHIV with resistance to all antiretroviral classes in Northern Uganda. [PDF]

IDCases
Kayinda F, Bakunzi LB, Okello E, Jurua C, Nasuuna EM.   +4 more
europepmc   +1 more source

Long-term outcomes of switching to BIC/FTC/TAF with or without prior INSTI experience: real-life data from a monocentric cohort of ART- experienced people with HIV

Objective: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is currently one of the most valuable switch options for antiretroviral therapy (ART)-experienced people with HIV (PWH).
Deborah Fiordelisi, Flavia Balena, Mariacristina Poliseno, Annalisa Saracino, Francesco Di Gennaro, Antonio Cianciaruso, Nicolo De Gennaro, Nicola Colavito   +7 more
core  

Evaluation of Real-World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir/Lamivudine Fixed-Dose Combination in Treatment-Naive and Pretreated People Living With HIV Who are Virologically Suppressed, in Routine Clinical Care in France: Results From the CARAVEL Study. [PDF]

Open Forum Infect Dis
Philibert P, Charpentier C, Naguleswaran N, Philippe C, Ajrouche R, Roustand L, Vouillot C, Hocqueloux L.   +7 more
europepmc   +1 more source